title: Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy.
abstract: BACKGROUND
  As there is no standard treatment for advanced gastric cancer refractory to first-line chemotherapy, the feasibility of S-1 plus weekly docetaxel combined with concurrent radiotherapy was evaluated.
  
  
  METHODS
  Ten patients were enrolled in this study. Patients were given S-1 at a daily dose of 40 mg/m(2) and docetaxel at a weekly dose of 20 mg/m(2) for 5 consecutive weeks, with concurrent radiotherapy (RT) amounting to a total irradiation dose of 45 Gy or 50.4 Gy.
  
  
  RESULTS
  Hematological toxicities were grade 3 or less except for anemia. Non-hematological toxicities were all grade 2 or less, apart from one grade 3 asthenia. There was one treatment-related death, resulting from melena, in a patient with a mechanical device in the radiation field. Planned treatment was delivered with relative dose intensity for S-1, docetaxel and RT as 94%, 98% and 97%, respectively. Median survival time of 297 days was obtained, with an objective response seen in 2 patients and symptom relief achieved in all patients.
  
  
  CONCLUSIONS
  S-1 plus weekly docetaxel combined with concurrent RT exhibited a tolerable toxicity profile with sufficient symptom palliation and prolonged survival in patients with advanced gastric cancer refractory to first-line chemotherapy.
authors: Department of Surgery, National Osaka Medical Center, 2-1-14, Hoenzaka, Chuoku, Osaka 540-0006, Japan. fujitani@onh.go.jp
authors: Kazumasa
authors: K
authors: Fujitani
authors: Toshimasa
authors: T
authors: Tsujinaka
authors: Hideya
authors: H
authors: Yamasaki
authors: Motohiro
authors: M
authors: Hirao
authors: Ken
authors: K
authors: Yoshida
authors: Yukinori
authors: Y
authors: Kurokawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid